163 related articles for article (PubMed ID: 20922461)
1. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.
Castaneda CA; Cortes-Funes H; Gomez HL; Ciruelos EM
Cancer Metastasis Rev; 2010 Dec; 29(4):751-9. PubMed ID: 20922461
[TBL] [Abstract][Full Text] [Related]
2. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer.
Dillon RL; White DE; Muller WJ
Oncogene; 2007 Feb; 26(9):1338-45. PubMed ID: 17322919
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.
Bartlett JM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S86-95. PubMed ID: 21115427
[TBL] [Abstract][Full Text] [Related]
4. [PI3K inhibitor].
Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
[TBL] [Abstract][Full Text] [Related]
5. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
[TBL] [Abstract][Full Text] [Related]
6. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Baselga J
Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
[TBL] [Abstract][Full Text] [Related]
7. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
[TBL] [Abstract][Full Text] [Related]
8. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
9. BacMam-enabled LanthaScreen cellular assays for PI3K/Akt pathway compound profiling in disease-relevant cell backgrounds.
Carlson CB; Mashock MJ; Bi K
J Biomol Screen; 2010 Mar; 15(3):327-34. PubMed ID: 20145103
[TBL] [Abstract][Full Text] [Related]
10. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
Georgakis GV; Younes A
Expert Rev Anticancer Ther; 2006 Jan; 6(1):131-40. PubMed ID: 16375650
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
12. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.
Lue H; Thiele M; Franz J; Dahl E; Speckgens S; Leng L; Fingerle-Rowson G; Bucala R; Lüscher B; Bernhagen J
Oncogene; 2007 Aug; 26(35):5046-59. PubMed ID: 17310986
[TBL] [Abstract][Full Text] [Related]
13. Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Wallin JJ; Guan J; Prior WW; Edgar KA; Kassees R; Sampath D; Belvin M; Friedman LS
Sci Transl Med; 2010 Sep; 2(48):48ra66. PubMed ID: 20826841
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
Porta C; Figlin RA
J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
[TBL] [Abstract][Full Text] [Related]
15. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
16. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer.
Kim D; Cheng GZ; Lindsley CW; Yang H; Cheng JQ
Curr Opin Investig Drugs; 2005 Dec; 6(12):1250-8. PubMed ID: 16370391
[TBL] [Abstract][Full Text] [Related]
17. ATP stimulates the proliferation of MCF-7 cells through the PI3K/Akt signaling pathway.
Bilbao PS; Santillán G; Boland R
Arch Biochem Biophys; 2010 Jul; 499(1-2):40-8. PubMed ID: 20450878
[TBL] [Abstract][Full Text] [Related]
18. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
Granville CA; Memmott RM; Gills JJ; Dennis PA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):679-89. PubMed ID: 16467077
[TBL] [Abstract][Full Text] [Related]
19. Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation.
Qiao M; Iglehart JD; Pardee AB
Cancer Res; 2007 Jun; 67(11):5293-9. PubMed ID: 17545609
[TBL] [Abstract][Full Text] [Related]
20. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
